{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:18:52Z","timestamp":1790317132836,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81560557"],"award-info":[{"award-number":["81560557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81560597"],"award-info":[{"award-number":["81560597"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.07.013","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T11:25:27Z","timestamp":1562325927000},"page":"15-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives"],"prefix":"10.1016","volume":"180","author":[{"given":"Wen-Jing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Wen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Xing","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu-Ri","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5534-4845","authenticated-orcid":false,"given":"Cheng Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.07.013_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.toxlet.2016.09.014","article-title":"Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury","volume":"262","author":"Yong","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2019.07.013_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Wang","year":"2010","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0676.1998.tb00120.x","article-title":"Signal transduction in hepatic stellate cells","volume":"18","author":"Pinzani","year":"1998","journal-title":"Liver"},{"key":"10.1016\/j.ejmech.2019.07.013_bib4","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cellsig.2009.05.008","article-title":"Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells","volume":"21","author":"Park","year":"2009","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2019.07.013_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.ejmech.2019.07.013_bib6","doi-asserted-by":"crossref","first-page":"e0153118","DOI":"10.1371\/journal.pone.0153118","article-title":"Characterization of the mmp\/timp imbalance and collagen production induced by IL-1 beta or TNF-alpha release from human hepatic stellate cells","volume":"11","author":"Robert","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.07.013_bib7","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.ejmech.2011.05.063","article-title":"Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors","volume":"46","author":"Jin","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/37284","article-title":"TGF-beta signalling from cell membrane to nucleus through SMAD proteins","volume":"390","author":"Heldin","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.07.013_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signaling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.07.013_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1797.2005.00334.x","article-title":"Transforming growth factor-beta and Smad signaling in kidney diseases","volume":"10","author":"Wang","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.ejmech.2019.07.013_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1745-7254.2007.00468.x","article-title":"Effect of TGF-beta\/smad signaling pathway on lung myofibroblast differentiation","volume":"28","author":"Gu","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2019.07.013_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1007\/s00018-006-6085-8","article-title":"Role of transforming growth factor-beta in the progression of heart failure","volume":"63","author":"Lim","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2019.07.013_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00042737-200402000-00001","article-title":"How can transforming growth factor beta be targeted usefully to combat liver fibrosis?","volume":"16","author":"Shek","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib14","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-\u03b2 in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.07.013_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0959-8049(02)00502-6","article-title":"Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression","volume":"39","author":"Inanovi\u0107","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2019.07.013_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2005.09.003","article-title":"Transforming growth factor-\u03b2 pathway: role in pancreas development and pancreatic disease","volume":"17","author":"Rane","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2019.07.013_bib17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7","volume":"65","author":"Byfield","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib18","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","article-title":"SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in\u00a0vitro and in\u00a0vivo","volume":"64","author":"Uhl","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.07.013_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","article-title":"Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice","volume":"44","author":"Bueno","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2019.07.013_bib20","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2019.07.013_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2895-4","article-title":"Phase I study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors","volume":"76","author":"Fujiwara","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib22","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A\u00a0phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib23","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib24","series-title":"Method of Manufacturing 3,3\u2019,-4, 4\u2019-tetraaminobiphenyl","author":"Yasuda","year":"2009"},{"key":"10.1016\/j.ejmech.2019.07.013_bib25","series-title":"Therapeutic Pyrazolyl Thienopyridines","author":"Barrett","year":"2008"},{"key":"10.1016\/j.ejmech.2019.07.013_bib26","series-title":"Phenyl Substituted Triazoles and Their Use as Selective Inhibitors of ALK5 Kinase","author":"Gaster","year":"2005"},{"key":"10.1016\/j.ejmech.2019.07.013_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejmech.2014.09.002","article-title":"Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-\u03b2 type-I receptor kinase (ALK5)","volume":"93","author":"Patel","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib28","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1016\/j.bmcl.2015.09.058","article-title":"Synthesis and biological evaluation of evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4- ([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-\u03b2 type I receptor kinase","volume":"25","author":"Krishnaiah","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.07.013_bib29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00018-014-1798-6","article-title":"EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-\u03b2\/Smad and ROS signaling","volume":"72","author":"Park","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2019.07.013_bib30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000438651","article-title":"TGF-\u03b2 type I receptor kinase inhibitor EW-719 suppress cholestatic liver fibrosis by inhibiting HIF1\u03b1-induced epithelial mesenchymal transition","volume":"38","author":"Kim","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1349-7006.2005.00103.x","article-title":"The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta","volume":"96","author":"Tojo","year":"2005","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2019.07.013_bib32","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.bmc.2011.03.008","article-title":"Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors","volume":"19","author":"Jin","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib33","series-title":"Aminopyrimidine Compounds and Methods of Use","author":"Smith","year":"2006"},{"key":"10.1016\/j.ejmech.2019.07.013_bib34","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.bmc.2014.10.001","article-title":"Rational design of novel CYP2A6 inhibitors","volume":"22","author":"Tani","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0040-4039(98)00140-3","article-title":"An improved and practical procedure for the synthesis of substituted phenylacetylpyridines","volume":"39","author":"Journet","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2019.07.013_bib36","series-title":"Spiro Compounds as Antagonists of TGF-Beta","author":"Sun","year":"2009"},{"key":"10.1016\/j.ejmech.2019.07.013_bib37","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.bmc.2007.01.055","article-title":"N6-[(Hetero)aryl\/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5\u2032-N-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor","volume":"15","author":"Baraldi","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib38","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1016\/j.bmc.2009.08.045","article-title":"Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase","volume":"17","author":"Zhang","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1074-5521(98)90170-3","article-title":"Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution","volume":"5","author":"Eyers","year":"1998","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.07.013_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ejmech.2016.12.005","article-title":"2,4-Disubstituted quinazolines as amyloid-\u03b2 aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: development and structure-activity relationship (SAR) studies","volume":"126","author":"Mohamed","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.013_bib41","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.3390\/molecules23123369","article-title":"Synthesis and evaluation of 3-substituted-4-(quinoxalin-6-yl)pyrzoles as TGF-\u03b2 type I receptor kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.07.013_bib42","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.bmcl.2009.02.087","article-title":"Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors","volume":"19","author":"Gellibert","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.07.013_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.phrs.2016.11.040","article-title":"Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation","volume":"117","author":"Jiang","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2019.07.013_bib44","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.biopha.2017.06.105","article-title":"Oligomeric proanthocyanidin derived from grape seeds inhibited NF-kB signaling in activated HSC: involvement of JNK\/ERK MAPK and PI3K\/Akt pathways","volume":"93","author":"Jiang","year":"2017","journal-title":"Biomed. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:51:17Z","timestamp":1778676677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419306348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":44,"alternative-id":["S0223523419306348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.013","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}